Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02455557 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Jun 2, 2026 to Sep 2, 2026v37
  2. Study completion pushed from Mar 2, 2026 to Jun 2, 2026v36
  3. Study completion date: Nov 30, 2025 to Mar 2, 2026v35
  4. Study completion date: Sep 30, 2025 to Nov 30, 2025v34
  5. Study completion date: Jun 30, 2025 to Sep 30, 2025v33
Show 31 earlier versionsHide 31 earlier versions
  1. Study completion date: Dec 30, 2024 to Jun 30, 2025v32
  2. Study completion date: Dec 30, 2023 to Dec 30, 2024v31
  3. 2 versions Re-verified since Mar 21, 2022, no change to tracked fieldsv29-v30
  4. Study completion date: Dec 30, 2021 to Dec 30, 2023
    • Collaborators shortened, about 4 words
    v28
  5. Eligibility criteria shortened, about 3 wordsv27
  6. Study completion date: Jan 30, 2021 to Dec 30, 2021v26
  7. Results first posted: Feb 1, 2021
    • Enrollment target: 64 to 66
    • Secondary endpoints revised (3)
    • Primary endpoint revised
    v25
  8. Study completion date: Oct 30, 2020 to Jan 30, 2021v24
  9. Study completion date: May 30, 2020 to Oct 30, 2020v23
  10. Re-verified, no change to tracked fieldsv22
  11. Primary completion date changed from estimate of Nov 28, 2019 to Oct 23, 2019v21
  12. Primary completion date: Jun 28, 2019 to Nov 28, 2019v20
  13. Primary completion date: Feb 28, 2019 to Jun 28, 2019
    • Study completion date: May 30, 2019 to May 30, 2020
    v19
  14. Primary completion date: Jan 1, 2019 to Feb 28, 2019v18
  15. Primary completion date: Nov 1, 2018 to Jan 1, 2019v17
  16. Primary completion date: Sep 1, 2018 to Nov 1, 2018v16
  17. Primary completion date: Jun 1, 2018 to Sep 1, 2018v15
  18. Primary completion date: May 30, 2018 to Jun 1, 2018v14
  19. Trial status: Recruiting to Active, Not Recruitingv13 Show 4 more changesShow less
    • Enrollment target: estimated 65 to confirmed 64
    • Primary completion date: Apr 2, 2018 to May 30, 2018
    • Study completion date: Apr 2, 2019 to May 30, 2019
    • Site details revised at 5 of 5 sites
  20. Enrollment target: 50 to 65v12
  21. Eligibility criteria expanded, about 30 wordsv11
  22. Primary completion date: Apr 2, 2017 to Apr 2, 2018
    • Study completion date: Apr 2, 2018 to Apr 2, 2019
    • Start date: May 5, 2015 to May 4, 2015
    v10
  23. Primary completion date: Apr 2017 to Apr 2, 2017v9 Show 5 more changesShow less
    • Study completion date: Apr 2, 2018
    • Start date: May 2015 to May 5, 2015
    • Eligibility criteria expanded, about 16 words
    • Study description expanded, about 8 words
    • Study sites revised (5)
  24. Study sites: 2 to 5v8
  25. Eligibility criteria shortened, about 20 words
    • Study sites revised (2)
    v7
  26. Re-verified, no change to tracked fieldsv6
  27. Site contacts updated at 1 of 2 sitesv5
  28. Site details revised at 1 of 2 sitesv4
  29. Re-verified, no change to tracked fieldsv3
  30. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells that express survivin. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without vaccine therapy in treating glioblastoma.
Trial Details
NCT Number NCT02455557
Lead Sponsor Roswell Park Cancer Institute
Conditions
(from sponsor)		 Glioblastoma, Gliosarcoma
Related terms Glioblastoma, Gliosarcoma
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov